Orally administered niclosamide-based organic/inorganic hybrid suppresses SARS-CoV-2 infection
G.-w. Jin, G. Choi, S. R. N, H. Piao, Y. B. Ryu, H.-J. Kwon, I. C. Lee, J.-H. Choy
This paper develops an orally administered niclosamide-based hybrid compound that suppresses SARS-CoV-2 infection in a Syrian hamster model, reducing inflammation and lung injury.
bioRxiv · Jul 19, 2022 · PreprintPharmacology & Toxicology